Улучшение подвижности после реваскуляризации при заболевании периферических артерий (IMPACT PAD)
УЛУЧШЕНИЕ МОБИЛЬНОСТИ ПОСЛЕ реваскуляризации при заболеваниях периферических артерий: исследование IMPACT PAD
Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.
Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.
In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
More than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually for Medicare beneficiaries who have lower extremity peripheral artery disease (PAD) without limb threatening ischemia, and rates of these procedures are increasing. In these patients, revascularization typically improves, but does not eliminate, PAD related walking impairment. Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.
Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. A large body of evidence, assembled over more than 25 years, supports our hypothesis that inorganic nitrate (such as that in nitrate-rich beetroot juice) will improve walking performance and other lower extremity outcomes after lower extremity revascularization.
Effective, accessible, and safe therapies are needed to enhance the benefits and improve durability of lower extremity revascularization. Therefore, in a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2). In Secondary Aims, the trial will establish whether home-based exercise, compared to control, and whether nitrate-rich beetroot juice, compared to placebo, improve the Walking Impairment Questionnaire and the PROMIS Mobility Questionnaire and prevent hemodynamic failure of the revascularized vessel. In exploratory aims, the trial will test the effects of the interventions on plasma nitric oxide bioavailability. If our hypotheses are correct, results of this trial will have a major impact on improving mobility in the large and growing number of people undergoing revascularization for disabling PAD.
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Mary M McDermott, MD
- Номер телефона: 312-503-6438
- Электронная почта: mdm608@northwestern.edu
Места учебы
-
-
Arizona
-
Tucson, Arizona, Соединенные Штаты, 85724
- Рекрутинг
- University of Arizona
-
Контакт:
- Wei Zhou, MD
-
-
California
-
Downey, California, Соединенные Штаты, 90242
- Рекрутинг
- Rancho Research Institute
-
Контакт:
- Tze-Woei Tan, MD
-
-
Florida
-
Tampa, Florida, Соединенные Штаты, 33606
- Рекрутинг
- University of South Florida
-
Контакт:
- Ulka Sachdev, MD
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30307
- Рекрутинг
- Emory University School of Medicine
-
Контакт:
- Olamide Alabi, MD
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60637
- Рекрутинг
- University of Chicago
-
Контакт:
- Tamar Polonsky, MD
- Номер телефона: 773-702-6153
-
Chicago, Illinois, Соединенные Штаты, 60611
- Рекрутинг
- Northwestern University Feinberg School of Medicine
-
Главный следователь:
- Mary M McDermott, MD
-
Контакт:
- Kathryn Domanchuk, BS
- Номер телефона: 312-503-6438
- Электронная почта: k-domanchuk@northwestern.edu
-
-
Michigan
-
Detroit, Michigan, Соединенные Штаты, 48202
- Рекрутинг
- Henry Ford Health
-
Контакт:
- Jonathan Ehrman, PhD
-
-
New Hampshire
-
Lebanon, New Hampshire, Соединенные Штаты, 03766
- Рекрутинг
- Dartmouth Hitchcock Medical Center
-
Контакт:
- Philip P Goodney, MD
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
Successful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.
Exclusion Criteria:
- History of leg amputation, not including toe and partial foot amputation
- Active gangrene
- Active limb threatening ischemia
- Already exercising at a level consistent with exercise intervention, using investigator discretion.
- Unstable angina
- Unwilling to drink study beverages
- Unwilling to adhere to the interventions and complete follow-up testing
- Currently taking sildenafil, tadalafil, or related drugs.
- Unwilling to accept randomization into either group (home-based exercise or attention control)
- Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.
- History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
- Baseline blood pressure <100/45.
- Wheelchair confinement or requiring a walker to ambulate
- Walking is limited by a condition other than PAD
- Current foot ulcer
- Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months
- Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.
- Allergy to beetroot juice
- Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.
- Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.
- Visual impairment that limits walking ability.
- Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.
- Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
- Planning to begin a supervised treadmill exercise program in the next 12 months.
- Heart attack or stroke in previous three months prior to baseline testing.
- An eGFR value <30 or potassium >5.0.
- In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Факторное присвоение
- Маскировка: Четырехместный
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Home based exercise + nitrate rich beetroot juice
This group will be participating in home based exercise and drinking nitrate rich beetroot juice for six months. |
This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention Participants will drink one shot of nitrate rich beet-root juice twice daily for six months. |
|
Плацебо Компаратор: Home-based exercise + placebo
This group will be participating in home based exercise and drinking placebo beetroot juice with nitrate removed for six months. |
This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months. |
|
Экспериментальный: Attention control + nitrate-rich beetroot juice
This group will be participating in attention control and drinking nitrate rich beetroot juice for six months. |
Participants will drink one shot of nitrate rich beet-root juice twice daily for six months. Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D. |
|
Плацебо Компаратор: Attention control + placebo
This group will be participating in attention control and drinking placebo beetroot juice with nitrate removed for six months. |
Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months. Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D. |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Six-Minute Walk Distance 6-month change
Временное ограничение: Baseline to 6-month follow-up
|
Distance walked in six minutes |
Baseline to 6-month follow-up
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Walking Impairment Questionnaire (WIQ) Distance Score 6-month change
Временное ограничение: Baseline to 6-month follow-up.
|
Patient reported ability to walk long distances. Score Range 0-100, 100 is best. |
Baseline to 6-month follow-up.
|
|
Walking Impairment Questionnaire (WIQ) Distance Score 12-month change
Временное ограничение: Baseline to 12-month follow-up
|
Patient reported ability to walk long distances. Score Range 0-100, 100 is best. |
Baseline to 12-month follow-up
|
|
PROMIS Mobility Questionnaire Score 6-month change
Временное ограничение: Baseline to 6-month follow-up
|
Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome. |
Baseline to 6-month follow-up
|
|
PROMIS Mobility Questionnaire Score 12-month change
Временное ограничение: Baseline to 12-month follow-up.
|
Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome. |
Baseline to 12-month follow-up.
|
|
Prevention of Hemodynamic Failure of The Revascularized Vessel
Временное ограничение: Baseline to 12 month follow-up
|
Hemodynamic failure consists of loss of patency of the revascularized vessel. The outcome will be adjudicated as a categorical outcome. Medical records between randomization and final follow-up will be obtained and reviewed by the IMPACT PAD adjudication committee, consisting of field center investigators and an interventional cardiologist. Participants who meet pre-defined criteria for hemodynamic failure of the revascularized vessel. |
Baseline to 12 month follow-up
|
|
Change in 6-minute walk distance
Временное ограничение: 12 month follow-up
|
Change in 6-minute walk distance between baseline and 12-month follow-up |
12 month follow-up
|
Другие показатели результатов
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Six-Minute Walk Distance
Временное ограничение: Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
|
Change in six-minute walk distance 24 hours after the final study beverage |
Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
|
|
Plasma Nitrite Levels
Временное ограничение: Baseline to 6-month follow-up
|
Change in plasma nitrite levels in the blood at 6-month follow-up |
Baseline to 6-month follow-up
|
|
BH4/BH2 6-month change
Временное ограничение: Baseline to 6-month follow-up
|
Change in BH4/BH2 ratio |
Baseline to 6-month follow-up
|
|
Progression of PAD
Временное ограничение: Baseline to 12-month follow-up
|
Determine whether home-based walking exercise, compared to attention control prevents progression of PAD, defined by any new lower extremity revascularization, acute limb ischemia, or amputation of either lower extremity between baseline and 12-month follow-up. |
Baseline to 12-month follow-up
|
Соавторы и исследователи
Спонсор
Спонсор
Соавторы
Соавторы
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Атеросклероз
- Артериосклероз
- Артериальные окклюзионные заболевания
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Заболевание периферических артерий
- Ограничение подвижности
- Заболевания периферических сосудов
- Перемежающаяся хромота
- Органические химические вещества
- Неорганические химические вещества
- Азотные соединения
- Анионы
- Ионы
- Электролиты
- Азотная кислота
- Нитраты
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- STU00222333
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Сроки обмена IPD
Data will be available at the time the primary outcome manuscript is submitted for publication and will be available for up to 10 years.
Критерии совместного доступа к IPD
Per BioLINCC
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .